Larimar Therapeutics Validates Skin as Surrogate for Friedreich’s Ataxia Biomarker — Larimar Therapeutics, Inc.

Event summary

Larimar Therapeutics published cross-species data showing nomlabofusp increases frataxin levels in clinically relevant tissues, correlating with skin and buccal cell measurements.
Findings support using skin frataxin concentrations as a surrogate endpoint for Friedreich’s ataxia (FA) under the FDA’s accelerated approval pathway.
Company plans to submit a Biologics License Application (BLA) for nomlabofusp in June 2026.

The big picture

Larimar Therapeutics’ findings strengthen the case for nomlabofusp as a disease-modifying therapy for Friedreich’s ataxia, leveraging cross-species data to support an accelerated regulatory pathway. The validation of skin as a surrogate biomarker could streamline clinical development and reduce reliance on invasive tissue sampling, addressing a critical unmet need in rare disease treatment.

What we're watching

Regulatory Pathway: Whether the FDA will accept skin frataxin levels as a surrogate endpoint for accelerated approval of nomlabofusp.
Clinical Execution: The pace at which Larimar can advance its BLA submission and secure regulatory approval by June 2026.
Market Differentiation: How nomlabofusp’s mechanism of action and surrogate biomarker validation will position it against potential competitors in Friedreich’s ataxia treatment.